||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Verona Pharma Share Discussion Threads
Showing 12601 to 12625 of 12625 messages
|Todays RNS another step forward...|
|Annual report now published
The AGM will be held on April 12th starting at 12:00, I plan to attend|
|Very interesting Tim and it looks like a change in strategy by AZ in disposing of the US rights of these aclidinium based treatments. As recently as November 2014 AZ made this statement in relation to Duaklir when they obtained EC marketing authorisation -
'The EU approval of Duaklir Genuair marks an important further step in AstraZeneca's inhaled therapy strategy of providing physicians and patients a choice of products uniquely available in both dry powder and pressurised metered dose devices.'
Why keep the EC rights yet give up the US rights? And Circassia propose to double their salesforce to promote Tudorza - so clearly they think that it's worth sinking money into promoting Tudorza whereas presumably AZ do not. I suspect that there's more to this than meets the eye as to the deal itself and the enhanced relationship between AZ and Circassia.
Still, the deal once again raises the question as to what price the EU and US rights for a novel treatment such as RPL554 - which to date has not shown the side effects of aclidinium based medicines - might bring at some point in the future.|
|AN interesting announcement today from Circassia. I'm not sure what's in it for AZ. I guess they may think they have more than enough irons in the fire with their respiratory development portfolio
|Timbo............and do you feel if it is marketed as a combo we would get any significant returns on share price bearing in mind the royalties also due to vernalis????????.Remember at old money 5p JAK said significant shareholder value. That in new money is £2.50 so would expect £5 to £7.50 and as a combo cannot see it. I would like your reasoning if you see the share price going to this. I do not and I personally am very disappointed but likelihood it is the best that we can expect under the current management and with the absence of any clinical leadership with Kathy now at GSK.|
shakin not stirred
|Agreed Tim. I think Verona will also adopt the same approach if the current trial for RPL554 in CF patients goes well. Current inhaled steroid treatments as stated on the CF Trust website -
'The most commonly-used inhaled steroids are beclometasone (Becotide, Clenil, QVAR) and budesonide (Pulmicort), which both come as beige and brown inhalers, and fluticasone (Flixotide), which is an orange inhaler.
Sometimes, steroids are combined in the same inhaler with a long-acting medicine that helps relax the muscles of the airways. These are Seretide (fluticasone plus salmeterol), which is a purple inhaler, or Symbicort (budesonide plus formoterol), which is a white turbohaler with a red base.'
So I would also expect a Phase 2 combo trial for CF down the line all being well.|
|>>>>>the bossman, I doubt if there will ever be widespread use of RPL554 as a replacement for salbutamol or ipratropium, more likely it will be used in addition to Salbutamol and ipratropium and hopefully (eventually) it will be marketed as a combo. That would be good enough for me!|
|I'm amazed Piers ~Morgan has enough free time to take on an additional role given his busy schedule.|
|I like this bit of info stands out...
When RPL554 was added to each of salbutamol or ipratropium bromide it caused a significant reduction (p=0.0002 and p=0.004 respectively) in trapped air in the lung (residual volume) as compared to salbutamol or ipratropium bromide alone, suggesting that RPL554 treatment may reduce dyspnea, a major debilitating symptom of COPD...
So maybe 554 can be used instead of salbutamol or ipratropium a nice little earner me thinks...
Also a few bob in the bank..
Net cash used in operating activities during the year of £5.59m (2015: £6.36m) reflecting clinical progress, with cash and cash equivalents as at 31 December, 2016 increasing to £39.79m (2015: £3.52m).|
|Excellent clinical summary in today's results of the NEW formulation - which is what has attracted the new institutional investors.
We have both statistically significant results at Phase 2 when used as part of a combo plus excellent safety profile, wide dosage range, longevity of effects in the lungs and the 'gold standard' of twice daily dosing.
RPL554 - in its new formulation - is clearly becoming a potentially very valuable clinical asset.|
|From this mornings RNS it looks like we are onto a winner..|
|Unless you bought in at a penny in which case showing a profit.|
shakin not stirred
|I am waiting to see if Nasdaq listing makes a difference but need to get to £2 new money to break even. Will bale out when that is reached. Unless anything materially changes as to indicating a good news flow. At the moment it is a Jam tomorrow as have been the last few years for me and longer for others. None of us have invested in companys for F.A. but that is the current return at this moment in time. That is the current reality of the share price.|
shakin not stirred
Whilst I share some of your frustration as to 'past performance', we are now focussed on a new suspension - and patented - formulation of RPL554. It is not the same formulation as in the CP/MW days and is now in trials for both CF and COPD - and these trials are important to establish efficacy and potential commercial value. And the current Phase 2a COPD trial IS important and will have been devised after appropriate consultations.
The current potential opportunities presented by these trials are why major investors have been attracted to the company and now hold far more shares than us PIs. Of course, as an AIM bio, we are all taking risks here - including institutional investors. But if you think that IIs and PIs have invested in a company just so as to keep management in jobs and to 'pick up their fat cat payslips for doing sweet F.A.' then surely the intelligent and logical thing for you to do is to sell up and move on.|
|Would like to share your confidence but I see this as another trial that will do nothing to move the value of the company forward and each year the board will just issue themselves more bonus shares etc etc. They must be rolling around with laughter each month that they pick up their fat cat payslips for doing sweet F.A. IMHO. Keep milking it JAK and CO. No improvement in share price since JAK has taken charge and he has proved that he only talks the talk. I hope his next job the employers and shareholders look back at what he did not do for this company and have second thoughts.Like CP and MW it appears JAK is just as hopeless IMHO...."significant shareholder value". Try being a comedian as you are good at that.|
shakin not stirred
|Agree Harold. If RPL554 can demonstrate efficacy within a combo with non of the side effects and perhaps additional benefits vis a vis control of exacerbations then there will inevitably be a lot of big pharma interest. Thus this Phase 2a study.
Re GSK's Seretide, for info - https://www.medicines.org.uk/emc/medicine/2317|
|Patients use spiriva long term with say seretide for copd.if the trial shows no problems and a benefit then there is a massive market for the combination.if it is then shown that it is superior to say seretide then somebody will jump at the chance to get their hands on it .of course the price of the product would have to be comparable to the products on the market. As gsk make seretide they will be rather upset they did not keep it.|
All current treatments for COPD can have significant side effects - which is why RPL554's excellent (to date) safety profile is potentially very significant.
Since you have to maintain the meds of seriously ill patients in a Phase 2a study of this nature, a combo with Spiriva - a tried and tested medication, but with potentially serious side effects for certain patients - makes sense in order to assess any enhanced benefits that RPL554 may add to the known data of Spiriva.
In particular, a combo with RPL554 may be more effective in dealing with exacerbations. See https://www.drugs.com/spiriva.html
Note the paragraph :-
'Spiriva is not a rescue medicine. It will not work fast enough to treat a COPD flare-up. Your doctor may prescribe a fast-acting inhalation medicine to treat a bronchospasm attack. Tell your doctor if it seems like your medications don't work as well.'
A combo with RPL554 may just solve that problem with regard to Spiriva - or some other similar treatment used by patients today.|
|Looking at the side effects I fail to see how this can be a good combination. Cannot see the point of combining with this drug. Like many on LSE board I feel the trials are becoming pointless and fruitless. I hate to say it but returning to trials that seem to be a grand waste of money and moving the commercialisation and share price no further forward. Very disappointing.|
shakin not stirred
|using RPL554 could be a good combo..
|>>>vas and Shakin'
Regarding royalty and milestone payments to Vernalis, the directors have always been cagey at offering any information. I suspect the reason for that is that they realize the wording in the original agreement may have been a bit vague and they prefer to let the lawyers work out what it all means, therefore all we have to go on is what there is in the AIM admission document, see link in the header and below:
|Vasilis. Yes there is a question that has never been really answered at the agm as to if these payments have a limiting date on them due to patent expiring that vernalis may hold.Otherwise I think that it may be quite a substantial 6-7p royalty plus milestone etc etc if I remember rightly. I think the milestone on commercialisation was a one off 50 million.|
shakin not stirred
|Phase 2a COPD trial official start as first patient dosed with expected top-line results in Q4 -
|From Vernalis's (VER) Interims this morning :-
'On the NCE pipeline, Verona announced positive data from a Phase IIa dose-finding clinical study for RPL554 in March 2016 using their new proprietary nebulised formulation and in May 2016, announced positive results from an "add-on" Phase II trial, where RPL554 produced over 60 per cent additional bronchodilation on top of standard of care bronchodilators in COPD patients. In order to finance the current and future studies of RPL554 in COPD and Cystic Fibrosis, Verona announced a US public offering in November 2016, targeting to raise up to $130 million in the first half of 2017. Vernalis will receive a share of sub-licensing income, a milestone payment on approval of RPL554 and royalties on commercialisation.'
From memory I'm still not aware of any specific numbers regarding the last sentence which clearly states Vernalis 'will' receive all three kinds of payment if things go as planned.|
|Yes, this is hardly going to plan but feel it will come back like a boomerang(probably hit me on the back of the head). However still feel lucky with this one. They will have accounted for this drop as worst case scenario as astute business leaders in this field. Perhaps a curve ball rns is to released prior to fund raising across the pond.|
shakin not stirred